This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

TSC Ratings' Updates: Abraxis BioScience

The following ratings changes were generated on Wednesday, March 18.

We've downgraded biotechnology company Abraxis BioScience (ABII) from hold to sell, driven by its feeble growth in its earnings per share and deteriorating net income.

Earnings per share declined steeply in the most recent quarter compared with the same quarter last year; in fact, the company has suffered a two-year pattern of declining EPS. Nte income fell from -$5.2 million in the year-ago quarter to -$181.9 million, significantly underperforming the S&P 500 and the biotechnology industry. The 93.5% gross profit margin is very high, though it has decreased from the same period last year. The -197.3% net profit margin significantly underperformed the industry average. Return on equity significantly underperforms the industry average and the S&P 500.

Shares are down 15.5% over the past year, reflecting in part the market's overall decline, which was actually deeper.

We've downgraded electronics distributor Arrow Electronics (ARW - Get Report) from hold to sell, driven by its deteriorating net income, disappointing return on equity, poor profit margins, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share.

Net income fell from $114 million in the year-ago quarter to -$871.9 million in the most recent quarter, significantly underperforming the S&P 500 and the electronic equipment, instruments and components industry. ROE also greatly decreased, a signal of major weakness within the corporations. Arrow's 12.7% gross profit margin is extremely low, having decreased from the year-ago quarter. EPS have declined by 893.5% compared with the year-ago quarter, though the consensus estimate suggests that the company's two-year trend of declining EPS should reverse in the coming year.
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
EPB $44.10 2.44%
ARW $62.10 0.00%
CLH $49.40 0.00%
HTH $19.86 0.00%
PENN $16.13 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs